Business
Maravai LifeSciences Appoints Bernd Brust as Chief Executive Officer and Member of its Board of Directors
SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to
About this update from Maravai Lifesciences Holdings, Inc.
[{"type":"text","content":"SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the appointment of Bernd Brust as Chief Executive Officer (CEO) and a member of the Board of Directors, effective immediately. Mr. Brust succeeds William “Trey” Martin III in these roles. “This leadership transition reflects Maravai’s commitment to accelerating innovation, execution, and financial performance. Bernd brings more than 30 years of leadership experience in the life sciences industry, with a proven track record of transforming businesses into profitable, revenue-growing companies with global product and service portfolios,” said R. Andrew Eckert, Chairman of the Board of Maravai LifeSciences. “We thank Trey for his contributions and vision, which we believe have positioned the company for future growth as we welcome Bernd to Maravai.” In addition, Mr. Brust’s customer-centric approach and background in transforming scientific organizations strongly align with Maravai’s mission to advance scientific discovery and innovation. His leadership reinforces Maravai’s commitment to delivering high-impact solutions to researchers and biotech innovators around the world. “I am honored to lead Maravai, a company perfectly positioned to serve the growing biologics and genomic medicine markets,” said Bernd Brust. “Maravai is grounded in innovation and powered by deep scientific excellence and passion for its customers. I look forward to working closely with the Board, team members, and customers to help advance breakthroughs from discovery to delivery.” “It has been a privilege to serve our customers, employees, and shareholders as Maravai’s CEO,” said Mr. Martin. “I am immensely proud of the genomic medicine platform we have built, and I thank each of our employees for their dedication to improving human health. I look forward to Maravai’s continued success.” Maravai LifeSciences remains well positioned for long-term success, backed by a strong financial foundation, a growing portfolio of innovative products, and a deep commitment to customer needs. The company looks to continue to expand its market leadership in mRNA, and bioprocess impurity detection and analytics, enhance manufacturing capabilities, and deliver differentia...